Denileukin Diftitox (Ontak®) and Total Skin Electron Beam Radiation (TSEB) in Patients with Treatment Refractory Cutaneus T-Cell Lymphoma: Report of Four Cases

被引：0
|
作者：
Buder, K. [1 ]
Mueller, P. A. [1 ]
Beckmann, G. [2 ]
Ugurel, S. [1 ]
Broecker, E. B. [1 ]
Becker, J. C. [1 ]
机构：
[1] Univ Wurzburg, Klin Dermatol Venerol & Allergol, D-97070 Wurzburg, Germany
[2] Univ Wurzburg, Klin Strahlentherapie, D-97070 Wurzburg, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2009年 / 7卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：847 / 847
页数：1
相关论文
共 50 条
  • [1] Denileukin Diftitox plus Total Skin Electron Beam Radiation in Patients with Treatment-refractory Cutaneous T-cell Lymphoma (Mycosis Fungoides): Report of Four Cases
    Buder, Kristina
    Mueller, Philip A.
    Beekmann, Gabriele
    Ugurel, Selma
    Broecker, Eva-Bettina
    Becker, Juergen C.
    ACTA DERMATO-VENEREOLOGICA, 2014, 94 (01) : 94 - 96
  • [2] Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK®)
    Talpur, R
    Apisarnthanarax, N
    Ward, S
    Duvic, M
    LEUKEMIA & LYMPHOMA, 2002, 43 (01) : 121 - 126
  • [3] Treatment of refractory peripheral T-cell lymphoma with denileukin difitox (ONTAK®).
    Talpur, R
    Apisarnthanarax, N
    Ward, S
    Sarris, A
    Duvic, M
    BLOOD, 2001, 98 (11) : 250B - 250B
  • [4] Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK®)
    Duvic, M
    Kuzel, T
    Olsen, EA
    Martin, AG
    Foss, FM
    Kim, YH
    Heald, PW
    Bacha, P
    Nichols, J
    Liepa, A
    CLINICAL LYMPHOMA, 2002, 2 (04): : 222 - 228
  • [5] Phase II study of denileukin diftitox (ONTAK) for relapsed/refractory T-cell non-Hodgkin's lymphoma
    Dang, NH
    Pro, B
    Fredrick, HR
    Samaniego, F
    Jones, D
    Rodriguez, M
    Goy, A
    Roaguera, J
    Walker, PL
    Younes, A
    Neelapu, S
    Kwak, L
    Fayad, L
    BLOOD, 2005, 106 (11) : 936A - 936A
  • [6] Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
    Foss, Francine M.
    Kim, Youn H.
    Prince, H. Miles
    Akilov, Oleg E.
    Querfeld, Christiane
    Seminario-Vidal, Lucia
    Fisher, David C.
    Kuzel, Timothy M.
    Yannakou, Costas K.
    Geskin, Larisa J.
    Feldman, Tatyana
    Sokol, Lubomir
    Allen, Pamela Blair
    Dang, Nam Hoang
    Cabanillas, Fernando
    Wong, Henry K.
    Ooi, Chean Eng
    Xing, Dongyuan
    Sauter, Nicholas
    Singh, Preeti
    Czuczman, Myron
    Duvic, Madeleine
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (10)
  • [7] Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak®) and bexarotene (Targretin®):: report of a case
    Kerl, K
    Prins, C
    Cerroni, L
    French, LE
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (05) : 988 - 991
  • [8] Interim analysis of a phase II study of denileukin diftitox (Ontak) for relapsed/refractory T-cell non-Hodgkin's lymphoma.
    Dang, NH
    Pro, B
    Hagemeister, FB
    Jones, D
    Samuels, B
    Rodriguez, MA
    Goy, A
    Romaguera, JE
    Walker, PL
    Kwak, L
    Fayad, L
    BLOOD, 2004, 104 (11) : 722A - 722A
  • [9] Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302
    Prince, H. Miles Miles
    Geskin, Larisa J.
    Akilov, Oleg E.
    Kuzel, Timothy M.
    Querfeld, Christiane
    Ooi, Chean Eng
    Xing, Dongyuan
    Sauter, Nicholas
    Singh, Preeti
    Czuczman, Myron
    Foss, Francine M.
    BLOOD, 2022, 140 : 6577 - 6578
  • [10] Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302
    Foss, Francine M.
    Kim, Youn H.
    Prince, H. Miles Miles
    Kuzel, Timothy M.
    Yannakou, Costas K.
    Ooi, Chean Eng
    Xing, Dongyuan
    Sauter, Nicholas
    Singh, Preeti
    Czuczman, Myron
    Duvic, Madeleine
    BLOOD, 2022, 140 : 1491 - 1492
12345